Anzeige
Mehr »
Montag, 13.04.2026 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 509722 | ISIN: SE0000722365 | Ticker-Symbol: OMAX
Frankfurt
13.04.26 | 09:24
0,001 Euro
-30,00 % -0,001
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
VIVESTO AB Chart 1 Jahr
5-Tage-Chart
VIVESTO AB 5-Tage-Chart
RealtimeGeldBriefZeit
0,0070,00818:03

Aktuelle News zur VIVESTO Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
01.04.Vivesto AB: The Board of Directors of Vivesto proposes a reverse share split and reduction of the share capital58The Board of Directors of Vivesto AB ("Vivesto" or the "Company") has resolved to propose that the Annual General Meeting on 7 May 2026 resolves on a reverse share split, whereby one hundred (100) existing...
► Artikel lesen
13.03.Vivesto AB: First dogs dosed in Vivesto's PK/toxicology study with Cantrixil140Solna, Sweden, March 13, 2026 - Vivesto AB, an oncology-focused development company, today announces that the first dogs have been dosed in the company's ongoing pharmacokinetic (PK) and toxicology...
► Artikel lesen
27.02.The observation status for Vivesto AB is removed134On November 20, 2025, the shares in Vivesto AB (the "Company") were given observation status with reference to uncertainty in respect of the issuer's financial position. Today, February 27,...
► Artikel lesen
VIVESTO Aktie jetzt für 0€ handeln
23.01.Vivesto AB: Vivesto announces outcome of the rights issue177NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONGKONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SINGAPORE,...
► Artikel lesen
02.01.Vivesto AB: Vivesto publishes information document regarding the rights issue255NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SINGAPORE...
► Artikel lesen
31.12.25XFRA CAPITAL ADJUSTMENT INFORMATION - 31.12.2025787Das Instrument OMAX SE0000722365 VIVESTO AB SK-,10 EQUITY wird cum Kapitalmassnahme gehandelt am 31.12.2025 und ex Kapitalmassnahme am 02.01.2026 The instrument OMAX SE0000722365 VIVESTO AB SK-,10 EQUITY...
► Artikel lesen
22.12.25Vivesto AB: Report from Extraordinary General Meeting in Vivesto AB156At the Extraordinary General Meeting in Vivesto AB ("Vivesto" or the "company") held on 22 December 2025, the following resolutions were passed. All resolutions were in accordance with the proposals...
► Artikel lesen
20.11.25Vivesto AB receives observation status229Today, November 20, 2025, Vivesto AB (the "Company") disclosed its interim report for the third quarter of 2025 with information on the Company's financial situation. The rules of Nasdaq Stockholm...
► Artikel lesen
07.11.25Vivesto AB: Vivesto reports positive interim results for Paccal Vet pilot study in dogs232Solna, Sweden, November 7, 2025 - Vivesto AB, an oncology-focused development company, today announced positive interim results obtained in Vivesto's open label, clinical pilot study with Paccal Vet...
► Artikel lesen
04.11.25Vivesto AB: Vivesto receives positive new Cantrixil preclinical results in AML200Solna, Sweden, November 4, 2025 - Vivesto AB, an oncology-focused development company, today announced that positive results were obtained from preclinical studies in an animal model of Acute Myeloid...
► Artikel lesen
14.08.25Vivesto AB: First patient dosed in Vivesto's Paccal Vet dose-finding study in cats226Solna, Sweden, August 14, 2025 - Vivesto AB, an oncology-focused development company, today announced that the first patient has been dosed in the company's Paccal Vet dose-finding study in cats with...
► Artikel lesen
11 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1